← Patent-cliff monitor small molecule ZEPBOUND TIRZEPATIDE
Loss of exclusivity July 2039 latest FDA-listed patent expiry
Company ELI LILLY AND CO
Drug detail Brand name ZEPBOUND Active ingredient TIRZEPATIDE Strength 15MG/0.5ML (15MG/0.5ML) Dosage form SOLUTION Route SUBCUTANEOUS Modality Small molecule FDA approval March 2024 Marketing status RX
Listed patents Patent Expires Type 12453758 July 2039 use U-4308 12343382 July 2039 use U-4409 12616740 July 2039 use U-4499 12453756 June 2039 product 11357820 June 2039 product 11918623 June 2039 use U-3855 12629404 June 2039 product 9474780 January 2036 substance, product
Regulatory exclusivity Code Expires I-958 December 2027 M-82 October 2027 NCE May 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.